


Lubiprostone



CAS

136790-76-6

Status

Commercial

Inquiry

Lubiprostone belongs to the group of prostaglandin derivatives and prostones. The active ingredient promotes regular defecation and improves constipation-associated symptoms. It is used for the treatment of chronic idiopathic constipation, irritable bowel syndrome and opioid-induced constipation.

Description

Formula	C ₂₀ H ₃₂ F ₂ O ₅
Molecular weight	390.46 g/mol
Molecular size	small
Controlled Substance	no
Precursor	no
Indications	Drugs for constipation

Your Contact



Marius Hang

International Division

Director API Export

Midas Pharma GmbH

Rheinstr. 49

55218 Ingelheim

Germany

[Send E-Mail](#)

Disclaimer

The information contained herein is the proprietary information of Midas Pharma GmbH and its affiliates. This information is provided to you solely for your evaluation, to determine your interest in a potential business relationship with Midas Pharma GmbH and/or its affiliates. Midas Pharma GmbH excludes any express or implied representations, guarantees or warranties of whatsoever nature, including but not limited to the warranties for the completeness or accuracy of the information provided herein.

No information provided herein – including any reference to any product or service – constitutes an offer for sale, or shall be construed as representing an offer for sale. In particular, nothing herein should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.